Literature DB >> 32072277

The possibility of endoscopic treatment of cN0 submucosal esophageal cancer: results from a surgical cohort.

Bo Ye1, Xiaobin Zhang1, Yuchen Su1, Shuguang Hao2, Haohua Teng3, Xufeng Guo1, Yu Yang1, Yifeng Sun1, Teng Mao1, Zhigang Li4.   

Abstract

BACKGROUND: We analyzed the pathological characteristics and recurrence pattern of cN0 submucosal esophageal cancer after esophagectomy and conducted risk stratification to determine the feasibility of performing endoscopic resection for cN0pT1b esophageal squamous cell malignancies.
METHODS: We retrospectively enrolled 167 patients who underwent right-sided transthoracic esophagectomy and extended thoracic/abdominal two-field lymphadenectomy. Patients with pathologically confirmed lymph node metastasis or tumor recurrence constituted the high-risk group for endoscopic submucosal resection, and the remainder were defined as low risk. Factors affecting lymphatic metastasis and long-term recurrence were identified by univariate and multivariate analyses.
RESULTS: Postoperative pathology showed that five patients (5/167; 3%) had lymph node metastases. Follow-up ranged from 12-60 months, with a median of 29 months. A total of 17 patients (10.2%) had recurrences during follow-up, including three patients with pathologic nodal metastasis (pN +) found at surgery. Invasion depth, differentiation, and tumor size differed significantly in high-risk patients. Overall 3-year survival rates were 94.2% (low-risk) and 40.9% (high-risk) (p < 0.01). Twenty-one patients with sm1 cancer, high tumor differentiation, and tumor length < 2 cm had no lymph node metastasis or lymphovascular invasion, and none of these patients experienced recurrence.
CONCLUSIONS: Endoscopic submucosal resection alone may be feasible for patients with small (≤ 2 cm) clinically N0 submucosal esophageal squamous cell carcinoma with low invasion depth (sm1) and higher differentiation, but prospective studies are required for confirmation. Other patients require surgical resection with extended two-field thoracic/abdominal lymphadenectomy.

Entities:  

Keywords:  Clinical N0 pathologic T1b; Endoscopic submucosal resection; Esophageal; Squamous cell carcinoma

Year:  2020        PMID: 32072277      PMCID: PMC7819934          DOI: 10.1007/s00464-020-07420-y

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  22 in total

1.  Predicting lymph node metastases in early esophageal adenocarcinoma using a simple scoring system.

Authors:  Lawrence Lee; Ulrich Ronellenfitsch; Wayne L Hofstetter; Gail Darling; Timo Gaiser; Christiane Lippert; Sebastien Gilbert; Andrew J Seely; David S Mulder; Lorenzo E Ferri
Journal:  J Am Coll Surg       Date:  2013-05-06       Impact factor: 6.113

Review 2.  The use of neural networks in identifying risk factors for lymph node metastasis and recommending management of t1b esophageal cancer.

Authors:  George Sgourakis; Ines Gockel; Orestis Lyros; Sophocles Lanitis; Georgia Dedemadi; Ursula Polotzek; Constantine Karaliotas; Hauke Lang
Journal:  Am Surg       Date:  2012-02       Impact factor: 0.688

Review 3.  Risk of lymph node metastasis in submucosal esophageal cancer: a review of surgically resected patients.

Authors:  Ines Gockel; George Sgourakis; Orestis Lyros; Ursula Polotzek; Carl Christoph Schimanski; Hauke Lang; Toshitaka Hoppo; Blair A Jobe
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2011-06       Impact factor: 3.869

Review 4.  Endoscopic submucosal dissection for superficial esophageal cancer.

Authors:  A A Aadam; S Abe
Journal:  Dis Esophagus       Date:  2018-07-01       Impact factor: 3.429

5.  Early esophageal cancer in Europe: endoscopic treatment by endoscopic submucosal dissection.

Authors:  Andreas Probst; Daniela Aust; Bruno Märkl; Matthias Anthuber; Helmut Messmann
Journal:  Endoscopy       Date:  2014-12-05       Impact factor: 10.093

6.  Depth of submucosal tumor infiltration and its relevance in lymphatic metastasis formation for T1b squamous cell and adenocarcinomas of the esophagus.

Authors:  Michael F Nentwich; Katharina von Loga; Matthias Reeh; Faik G Uzunoglu; Andreas Marx; Jakob R Izbicki; Dean Bogoevski
Journal:  J Gastrointest Surg       Date:  2013-10-04       Impact factor: 3.452

Review 7.  Endoscopic and surgical resection of T1a/T1b esophageal neoplasms: a systematic review.

Authors:  George Sgourakis; Ines Gockel; Hauke Lang
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

Review 8.  Early squamous cell carcinoma of the oesophagus: the Japanese viewpoint.

Authors:  K Takubo; J Aida; M Sawabe; M Kurosumi; M Arima; M Fujishiro; T Arai
Journal:  Histopathology       Date:  2007-07-06       Impact factor: 5.087

9.  Predictors of major morbidity and mortality after esophagectomy for esophageal cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database risk adjustment model.

Authors:  Cameron D Wright; John C Kucharczuk; Sean M O'Brien; Joshua D Grab; Mark S Allen
Journal:  J Thorac Cardiovasc Surg       Date:  2009-03       Impact factor: 5.209

10.  A phase II trial of combined treatment of endoscopic mucosal resection and chemoradiotherapy for clinical stage I esophageal carcinoma: Japan Clinical Oncology Group Study JCOG0508.

Authors:  Yukinori Kurokawa; Manabu Muto; Keiko Minashi; Narikazu Boku; Haruhiko Fukuda
Journal:  Jpn J Clin Oncol       Date:  2009-08-24       Impact factor: 3.019

View more
  2 in total

1.  Influence of Lymphangio vascular (V) and perineural (N) invasion on survival of patients with resected esophageal squamous cell carcinoma (ESCC): a single-center retrospective study.

Authors:  Chengke Xie; Zhiyao Chen; Jie Xu; Zhiyong Meng; Zhijun Huang; Jianqing Lin
Journal:  PeerJ       Date:  2022-03-02       Impact factor: 2.984

Review 2.  Management of Superficial Esophageal Squamous Cell Carcinoma and Early Gastric Cancer following Non-Curative Endoscopic Resection.

Authors:  Waku Hatta; Tomoyuki Koike; Kaname Uno; Naoki Asano; Atsushi Masamune
Journal:  Cancers (Basel)       Date:  2022-08-02       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.